Generic placeholder image

Current HIV Research


ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors

Author(s): Zuhal Yeşilbağ*, Emine İlay Şengül, Sevtap Şenoğlu, Özlem Altuntaş Aydın and Hayat Kumbasar Karaosmanoğlu

Volume 18, Issue 6, 2020

Page: [415 - 425] Pages: 11

DOI: 10.2174/1574885515666200812215140

Price: $65


Background: Long life expectancy in people living with human immunodeficiency virus (PLWH) caused an increase in comorbidities and co-medications. We aimed to analyse comedications and drug-drug interactions (DDIs) in antiretroviral therapy (ART)-naive PLWH in the era of integrase inhibitors.

Methods: A retrospective observational study was conducted between January 2016-August 2019. Patients’ characteristics and chronic co-medications were recorded. The University of Liverpool HIV drug interaction database was used for DDIs.

Results: Among 745 patients, the chronic co-medication rate was 30.9%. Older age (p<0.001, OR:6.66, 95% CI: 3.86-11.49) and female gender (p=002, OR:2.25, 95%:1.14-4.44) were independently associated with co-medication. Cardiovascular system (CVS) and central nervous system (CNS) drugs were the most common co-medications. Older age patients (p<0.001, OR:12.04, 95% CI:4.63-36.71), having heterosexual (HS) contact (p=0.003, OR:3.8, 95% CI:1.57-9.22) were independently associated with CVS drugs use, while being men who have sex with men (MSM) (p=0.03, OR:2.59, 95% CI:1.11-6.03) were associated with CNS drugs use. DDIs were seen in 37.4% of patients with co-medications. Antidiabetics (23.3%), CNS (22.1%) and CVS drugs (19.8%) most commonly had DDIs. Contraindication was most commonly seen between inhaled corticosteroids and elvitegravir/cobicistat. A number of non-ART drugs, elvitegravir/cobicistat, antidiabetics, vitamins were independently associated with the presence of DDIs.

Conclusion: Results suggested the need for attention about co-medication in PLWH regardless of whether they are young or older. CNS drugs should be questioned more detailed in MSM, as well as CVS drugs in older HS patients. Elvitegravir/cobicistat is significantly associated with DDIs and switching to an unboosted INSTI should be considered in patients with multiple comorbidities.

Keywords: Co-medication, drug-drug interactions, elvitegravir/cobicistat, HIV, inhaled drugs, integrase inhibitors.

Graphical Abstract
Palella FJ Jr, Delaney KM, Moorman AC, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853-60.
[] [PMID: 9516219]
Marzolini C, Back D, Weber R, et al. Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66(9): 2107-11.
[] [PMID: 21680580]
Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther (Lond) 2012; 17(5): 833-40.
[] [PMID: 22358155]
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376(9734): 49-62.
[] [PMID: 20609987]
Seden K, Merry C, Hewson R, et al. Prevalence and type of drug- drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. J Antimicrob Chemother 2015; 70(12): 3317-22.
[] [PMID: 26286575]
Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47(4): 542-53.
[] [PMID: 18627268]
Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interv Aging 2013; 8: 749-63.
[PMID: 23818773]
Allavena C, Hanf M, Rey D, et al. Dat’AIDS study group. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. PLoS One 2018; 13(9): e0203895.
[] [PMID: 30240419]
Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol 2019; 12(7): 643-59.
[] [PMID: 31155978]
Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53(11): 1120-6.
[] [PMID: 21998278]
Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7(2): 69-76.
[] [PMID: 20425560]
Work Group for HIV and Aging Consensus Project. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60(5): 974-9.
[] [PMID: 22568508]
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30(8): 613-28.
[] [PMID: 23740523]
Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc 2020; 23(2): e25449.
[] [PMID: 32011104]
Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc 2014; 62(3): 447-53.
[] [PMID: 24576251]
Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309(13): 1397-405.
[] [PMID: 23549585]
Ware D, Palella FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One 2018; 13(9): e0203890.
[] [PMID: 30204807]
Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009; 64(1): 5-8.
[] [PMID: 19398457]
Molas E, Luque S, Retamero A, et al. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team. HIV Clin Trials 2018; 19(1): 1-7.
[] [PMID: 29179644]
Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007; 27(10): 1379-86.
[] [PMID: 17896893]
Kigen G, Kimaiyo S, Nyandiko W, et al. USAID-Academic Model for Prevention Treatment of HIV/AIDS. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One 2011; 6(2): e16800.
[] [PMID: 21373194]
Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011; 45(3): 317-24.
[] [PMID: 21386025]
Tseng A, Foisy M. Important drug-drug interactions in HIVinfected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012; 14(1): 67-82.
[] [PMID: 22125049]
Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50(10): 1419-21.
[] [PMID: 20380564]
Iniesta-Navalón C, Franco-Miguel JJ, Gascón-Cánovas JJ, Rentero-Redondo L. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach. HIV Med 2015; 16(5): 273-9.
[] [PMID: 25523089]
de Maat MM, de Boer A, Koks CH, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004; 29(2): 121-30.
[] [PMID: 15068400]
Seden K, Bradley M, Miller AR, Beadsworth MB, Khoo SH. The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. Int J STD AIDS 2013; 24(3): 237-41.
[] [PMID: 23562967]
Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I. Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa. S Afr Med J 2008; 98(2): 109-13.
[PMID: 18350204]
Avihingsanon A, van der Lugt J, Singphore U, et al. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. AIDS Res Hum Retroviruses 2012; 28(10): 1170-6.
[] [PMID: 22250979]
Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300(5): 530-9.
[] [PMID: 18677025]
von Wyl V, Yerly S, Böni J, et al. Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008; 46(8): 1299-309.
[] [PMID: 18444871]
Negredo E, Moltó J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18(3): 459-63.
[] [PMID: 15090798]
Seden K, Khoo SH, Back D, et al. Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. J Antimicrob Chemother 2013; 68(1): 1-3.
[] [PMID: 22915459]
Okulicz JF, Grandits GA, French JA, et al. Infectious Disease Clinical Research Program (IDCRP) HIV Working Group. Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther 2011; 8: 18.
[] [PMID: 21575228]
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5): 563-72.
[] [PMID: 16652030]
Agu KA, Oqua D, Adeyanju Z, et al. The incidence and types of medication errors in patients receiving antiretroviral therapy in resource-constrained settings. PLoS One 2014; 9(1): e87338.
[] [PMID: 24489899]
Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N. Comparing the frequencies of contraindicated drug-drug interactions between differing antiretroviral regimens in HIV-infected patients. Ann Pharmacother 2017; 51(5): 365-72.
[] [PMID: 28367698]
Patel N, Borg P, Haubrich R, McNicholl I. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm 2018; 75(15): 1132-9.
[] [PMID: 29903710]
Farhoudi M, Khalili H, Karimzadeh I, Abbasian L. Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center. Expert Opin Drug Metab Toxicol 2015; 11(4): 471-9.
[] [PMID: 25557864]
Yiu P, Nguyen NN, Holodniy M. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy 2011; 31(5): 480-9.
[] [PMID: 21923429]
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA 2018; 320(4): 379-96.
[] [PMID: 30043070]
Liverpool HIV drug interactions
Smit M, Brinkman K, Geerlings S, et al. ATHENA observational cohort. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15(7): 810-8.
[] [PMID: 26070969]
Hasse B, Ledergerber B, Furrer H, et al. Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53(11): 1130-9.
[] [PMID: 21998280]
Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45(12): 1593-601.
[] [PMID: 18190322]
Mothe B, Perez I, Domingo P, et al. HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res 2009; 7(6): 597-600.
[] [PMID: 19929794]
Bastida C, Grau A, Márquez M, et al. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm Hosp 2017; 41(5): 618-24.
[PMID: 28847251]
Gimeno-Gracia M, Crusells-Canales MJ, Javier Armesto-Gómez F, Rabanaque-Hernández MJ. Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV Clin Trials 2015; 16(3): 117-24.
[] [PMID: 25978302]
Marzolini C, Elzi L, Gibbons S, et al. Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (Lond) 2010; 15(3): 413-23.
[] [PMID: 20516560]
Baecke C, Gyssens IC, Decoutere L, van der Hilst JCH, Messiaen P. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study. Neth J Med 2017; 75(6): 235-40.
[PMID: 28741582]
Ruzicka DJ, Imai K, Takahashi K, Naito T. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database. BMJ Open 2018; 8(6): e019985.
[] [PMID: 29903786]
Córdova E, Porteiro N, Loiza E, Mingrone H. [Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, Argentina]. Rev Chilena Infectol 2016; 33(Suppl. 1): 54-9.
[PMID: 28453027]
Schlaeppi C, Vanobberghen F, Sikalengo G, et al. Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) study group. Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. HIV Med 2020; 21(1): 53-63.
[] [PMID: 31532898]
Kara E, İnkaya AÇ, Aydın Haklı D, Demirkan K, Ünal S. Polypharmacy and drug-related problems among people living with HIV/AIDS: a single-center experience. Turk J Med Sci 2019; 49(1): 222-9.
[] [PMID: 30761883]
Gebo KA, Justice A. HIV infection in the elderly. Curr Infect Dis Rep 2009; 11(3): 246-54.
[] [PMID: 19366568]
Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11(2): 100-9.
[] [PMID: 20542846]
Loikas D, Wettermark B, von Euler M, Bergman U, Schenck- Gustafsson K. Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open 2013; 3(5): e002378.
[] [PMID: 23645921]
Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014; 23(2): 112-9.
[] [PMID: 24206025]
Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005; 25(4): 433-57.
[] [PMID: 15914265]
Justice AC, McGinnis KA, Atkinson JH, et al. Veterans Aging Cohort 5-Site Study Project Team. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18(Suppl. 1): S49-59.
[] [PMID: 15075498]
Sivasubramanian M, Mimiaga MJ, Mayer KH, et al. Suicidality, clinical depression, and anxiety disorders are highly prevalent in men who have sex with men in Mumbai, India: findings from a community-recruited sample. Psychol Health Med 2011; 16(4): 450-62.
[] [PMID: 21749242]
Jiang T, Zhou X, Wang H, et al. Psychosocial factors associated with quality of life in young men who have sex with men living with HIV/AIDS in Zhejiang, China. Int J Environ Res Public Health 2019; 16(15): 2667.
[] [PMID: 31349674]
Holtzman C, Armon C, Tedaldi E, et al. and the HOPS Investigators. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med 2013; 28(10): 1302-10.
[] [PMID: 23605401]
Siefried KJ, Mao L, Cysique LA, et al. PAART study investigators. Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS 2018; 32(1): 35-48.
[] [PMID: 29135584]
Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 2013; 47(11): 1429-39.
[] [PMID: 24285760]
Ranzani A, Oreni L, Agrò M, et al. Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older. J Acquir Immune Defic Syndr 2018; 78(2): 193-201.
[] [PMID: 29767640]
Chen R, Chen J, Tang Q, et al. Use of comedications and potential drug-drug interactions in people living with HIV in China. J Infect Chemother 2020; 26(7): 722-8.
[] [PMID: 32354599]
Núñez-Núñez M, Castañeda-Macías I, Sandoval-Fernández Del Castillo S. Potential interactions in a cohort of elderly hiv-positive patients. Farm Hosp 2018; 42(4): 163-7.
[PMID: 29959841]
Demessine L, Peyro-Saint-Paul L, Gardner EM, Ghosn J, Parienti JJ. Risk and cost associated with drug-drug interactions among aging HIV patients receiving combined antiretroviral therapy in France. Open Forum Infect Dis 2019; 6(3): ofz051.
[] [PMID: 30949521]
López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan Á, et al. Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study. Clin Infect Dis 2019; ciz811.
World Health Organization (WHO). Updated recommendations on fırst-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 2018.
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.
Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2019.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy